Table 4.
Changes of NPDR stage in the two study groups.
| Study Group and Visits |
Total Patients/Eyes |
NPDR Stage, Number of Eyes (%) | Within-Group p Value * |
||
|---|---|---|---|---|---|
| Mild | Moderate | Severe | |||
| DHA group | |||||
| Baseline | 83/154 | 95 (61.7) | 54 (35.1) | 5 (3.2) | |
| 6 months | 75/139 | 87 (62.6) | 46 (33.1) | 6 (4.3) | 0.902 |
| 12 months | 69/126 | 89 (70.6) | 30 (23.8) | 7 (5.5) | 0.171 |
| 18 months | 66/126 | 84 (69.4) | 29 (24.0) | 8 (6.6) | 0.189 |
| 24 months | 59/121 | 81 (75.7) | 20 (18.7) | 6 (5.6) | 0.120 |
| Placebo group | |||||
| Baseline | 87/163 | 101 (61.9) | 60 (36.8) | 2 (1.3) | |
| 6 months | 81/151 | 111 (73.5) | 40 (26.5) | 0 | 0.025 |
| 12 months | 72/133 | 98 (73.7) | 29 (21.8) | 6 (4.5) | 0.004 |
| 18 months | 70/131 | 88 (67.2) | 43 (32.8) | 0 | 0.275 |
| 24 months | 63/119 | 87 (73.1) | 31 (26.0) | 1 (0.8) | 0.084 |
* McNemar–Bowker test.